Tickertape - Financial freedom begins here
- NIFTY 5024,576.600.87% 211.75
- SENSEX79,273.330.96% 753.03
- MARKET MOOD10:27
Greed
Market and sectors
See All| NIFTY 100 Largecap | 25,468.700.85% | |
| NIFTY 100 Midcap | 60,127.600.56% | |
| NIFTY 100 Smallcap | 17,652.850.95% |
| NIFTY Bank | 57,347.451.35% | |
| NIFTY IT | 31,747.050.51% | |
| NIFTY Pharma | 22,446.550.05% |
| NIFTY 100 Largecap | 25,468.700.85% | |
| NIFTY 100 Midcap | 60,127.600.56% | |
| NIFTY 100 Smallcap | 17,652.850.95% |
| NIFTY Bank | 57,347.451.35% | |
| NIFTY IT | 31,747.050.51% | |
| NIFTY Pharma | 22,446.550.05% |
Today's stocks
| STOCKSPRICECHANGE | |
₹214.019.13% | |
Nestle India LtdNESTLEIND | ₹1,379.907.27% |
₹3,509.806.50% | |
₹485.103.98% | |
Hindustan Unilever LtdHINDUNILVR | ₹2,310.703.55% |
Mutual funds and ETFs
| FUNDSRETURNS | |
Equity • Growth | |
8.47% Equity • Growth | |
Equity • Growth | |
7.70% Equity • Growth | |
Equity • Growth |
Curated screens and deals
Market and sectors
See All| NIFTY 100 Largecap | 25,468.700.85% | |
| NIFTY 100 Midcap | 60,127.600.56% | |
| NIFTY 100 Smallcap | 17,652.850.95% |
| NIFTY Bank | 57,347.451.35% | |
| NIFTY IT | 31,747.050.51% | |
| NIFTY Pharma | 22,446.550.05% |
| NIFTY 100 Largecap | 25,468.700.85% | |
| NIFTY 100 Midcap | 60,127.600.56% | |
| NIFTY 100 Smallcap | 17,652.850.95% |
| NIFTY Bank | 57,347.451.35% | |
| NIFTY IT | 31,747.050.51% | |
| NIFTY Pharma | 22,446.550.05% |
Today's stocks
| STOCKSPRICECHANGE | |
₹214.019.13% | |
Nestle India LtdNESTLEIND | ₹1,379.907.27% |
₹3,509.806.50% | |
₹485.103.98% | |
Hindustan Unilever LtdHINDUNILVR | ₹2,310.703.55% |
Curated screens and deals
Shadowfax Technologies announced the launch of Shadowfax 360, a unified digital shipping platform built to empower India's SME and D2C ecosystem. Shadowfax 360 provides small sellers and emerging brands with immediate access to an enterprise grade network covering 15,000+ pincodes across 2,500 cities. Designed to solve core merchant pain points, the platform features a first-of-its-kind transparent flat-rate billing model that eliminates weight-based disputes, one-click integrations with major sales channels like Shopify and WooCommerce, and an AI-driven RTO Predictor to minimize return risks. To support SME liquidity, the platform also offers the industry's fastest Cash on Delivery (COD) remittance cycles. The self serve portal enables businesses to bypass traditional logistics onboarding hurdles, allowing them to register and start nationwide shipping in minutes. Unlike traditional logistics partnerships that demand volume commitments, Shadowfax 360 imposes no minimum order requirements - making enterprise-grade logistics accessible to every SME, regardless of size or stage. The launch marks an important step in the Company's efforts to scale its seller ecosystem and diversify its merchant base beyond enterprise and marketplace relationships - expanding to a broader base of online-first SMEs, early-stage D2C brands and marketplace-first sellers transitioning to owned-channel commerce. The Company expects Shadowfax 360 to be a meaningful driver of new customer acquisition in the years ahead, contributing to volume growth and revenue diversification.
GRM Overseas has announced the launch of its 10X Basmati Rice Suitable for Diabetics. The product will be rolled out across key International and Domestic markets, marking an important step in GRM's strategy to expand its health-focused product portfolio globally. This new launch addresses the rising demand for healthier dietary choices on account of rising diabetes prevalence, urban lifestyles, and health awareness across markets.
Glaxosmithkline Pharmaceuticals announced that Vinay Subramanian, Commercial Head - Oncology would be part of leadership team effective 20 April 2026 based out of Mumbai, and he would be part of senior Management Personnel of the Company effective the said date. Vinay brings with him over 24 years of experience in the Pharmaceuticals, Life Science. Healthcare Devices, and Medical Technology sectors. Prior to joining GSK. he served as the India Enabling leader - Enterprise & Neighboring Countries at Roche Products India Pvt ltd. where he was responsible for the immunotherapy portfolio and was part of their leadership team.
Mutual funds and ETFs
| FUNDSRETURNS | |
Equity • Growth | |
8.47% Equity • Growth | |
Equity • Growth | |
7.70% Equity • Growth | |
Equity • Growth |
Money
Matters
- Assets tracked worth60,500 Cr
- Loved by60 L+ investors
- Downloads6.2M+
- Rated on Google Play4.2



%20(1)_BKz_bMFSp.png)
